The Food and Drug Administration (FDA) has posted a discontinuation notice for Capital and Codeine (acetaminophen, codeine phosphate; Valeant) Oral Suspension.
Capital and Codeine Oral Suspension combines codeine, a centrally-acting analgesic, with acetaminophen, a peripherally-acting analgesic. It is indicated for the relief of mild to moderate pain.
Capital and Codeine, a CV controlled substance, was supplied as a 120mg/12mg per 5mL fruit punch-flavored suspension in 16oz bottles (NDC 0187-0003-01). The Company stated that the product discontinuation was a result of a business decision.
For more information call (800) 321-4576 or visit Valeant.com.